Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Circulation：IDO，急性心肌梗死治疗的新靶点！

2021-02-14 MedSci原创 MedSci原创

急性心肌梗死IDO吲哚胺2,3 -双加氧酶1
关注

吲哚胺2,3 -双加氧酶1 (IDO)催化L-色氨酸代谢的一个限速步骤，还是多种病理条件的重要调节因子。

缺血性心血管疾病，特别是急性心肌梗死(MI)，是世界范围内主要的死亡原因之一。吲哚胺2,3 -双加氧酶1 (IDO)催化L-色氨酸代谢的一个限速步骤，还是多种病理条件的重要调节因子。Melhem等人推测IDO可能在MI后心脏稳态的局部调节中起关键作用。

本研究分析了具有不同特异性细胞IDO缺陷的小鼠的心肌修复（特异性细胞包括：内皮细胞、平滑肌细胞、心肌细胞、髓细胞，以及急性心肌梗死时的心肌修复。

IDO缺陷/抑制可限制MI后的心脏功能障碍

研究结果显示，小鼠MI后通过IDO产生的肾素受到明显诱导。敲除或药理抑制IDO会限制MI后的心脏损伤和心功能障碍。平滑肌细胞、炎症细胞或心肌细胞的IDO功能明显丧失并不影响小鼠MI后的心脏功能和心室重构。

IDO缺陷/抑制可改善MI后心肌恢复

与此明显不同的是，内皮细胞特异性缺失IDO的小鼠的心脏功能和心肌细胞收缩能力均有所改善，而且不良心室重构也有所减弱。给IDO缺陷的小鼠补充犬尿氨酸可减弱IDO敲除的保护作用。犬尿氨酸通过一种芳基烃受体依赖性的机制产生活性氧来促进心肌细胞凋亡。

本研究数据表明，IDO可成为急性心肌梗死治疗的新靶点。

原始出处：

Nada Joe Melhem, et al. Endothelial Cell Indoleamine 2, 3-Dioxygenase 1 Alters Cardiac Function After Myocardial Infarction Through Kynurenine. Circulation. 2021;143:566–580

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703532, encodeId=5fc71e035329c, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Thu Mar 25 18:48:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965379, encodeId=eb459653e9ae, content=<a href='/topic/show?id=0bf94e52dc' target=_blank style='color:#2F92EE;'>#Circulation#</a> 插入话题+积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4752, encryptionId=0bf94e52dc, topicName=Circulation)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Thu May 13 23:04:48 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288316, encodeId=2f2012883161d, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 16 07:48:04 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924658, encodeId=823e92465855, content=i do, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Mon Feb 15 07:57:47 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924595, encodeId=1d0a9245952e, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Feb 14 17:01:23 CST 2021, time=2021-02-14, status=1, ipAttribution=)]
    2021-03-25 tongyongming

    #IDO#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1703532, encodeId=5fc71e035329c, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Thu Mar 25 18:48:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965379, encodeId=eb459653e9ae, content=<a href='/topic/show?id=0bf94e52dc' target=_blank style='color:#2F92EE;'>#Circulation#</a> 插入话题+积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4752, encryptionId=0bf94e52dc, topicName=Circulation)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Thu May 13 23:04:48 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288316, encodeId=2f2012883161d, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 16 07:48:04 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924658, encodeId=823e92465855, content=i do, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Mon Feb 15 07:57:47 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924595, encodeId=1d0a9245952e, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Feb 14 17:01:23 CST 2021, time=2021-02-14, status=1, ipAttribution=)]
    2021-05-13 MedSciZeng

    #Circulation# 插入话题+积分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1703532, encodeId=5fc71e035329c, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Thu Mar 25 18:48:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965379, encodeId=eb459653e9ae, content=<a href='/topic/show?id=0bf94e52dc' target=_blank style='color:#2F92EE;'>#Circulation#</a> 插入话题+积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4752, encryptionId=0bf94e52dc, topicName=Circulation)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Thu May 13 23:04:48 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288316, encodeId=2f2012883161d, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 16 07:48:04 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924658, encodeId=823e92465855, content=i do, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Mon Feb 15 07:57:47 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924595, encodeId=1d0a9245952e, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Feb 14 17:01:23 CST 2021, time=2021-02-14, status=1, ipAttribution=)]
    2021-02-16 lsndxfj

    #新靶点#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1703532, encodeId=5fc71e035329c, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Thu Mar 25 18:48:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965379, encodeId=eb459653e9ae, content=<a href='/topic/show?id=0bf94e52dc' target=_blank style='color:#2F92EE;'>#Circulation#</a> 插入话题+积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4752, encryptionId=0bf94e52dc, topicName=Circulation)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Thu May 13 23:04:48 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288316, encodeId=2f2012883161d, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 16 07:48:04 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924658, encodeId=823e92465855, content=i do, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Mon Feb 15 07:57:47 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924595, encodeId=1d0a9245952e, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Feb 14 17:01:23 CST 2021, time=2021-02-14, status=1, ipAttribution=)]
    2021-02-15 carrotlyl

    i do

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1703532, encodeId=5fc71e035329c, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Thu Mar 25 18:48:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965379, encodeId=eb459653e9ae, content=<a href='/topic/show?id=0bf94e52dc' target=_blank style='color:#2F92EE;'>#Circulation#</a> 插入话题+积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4752, encryptionId=0bf94e52dc, topicName=Circulation)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Thu May 13 23:04:48 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288316, encodeId=2f2012883161d, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Feb 16 07:48:04 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924658, encodeId=823e92465855, content=i do, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Mon Feb 15 07:57:47 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924595, encodeId=1d0a9245952e, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Feb 14 17:01:23 CST 2021, time=2021-02-14, status=1, ipAttribution=)]
    2021-02-14 医鸣惊人

    认真学习了

    0

相关资讯

Hepatology: 肝移植前心脏导管插入术与心肌梗塞和心脏死亡率降低相关联

单独的超声心动图检查不能可靠地筛查LT患者心血管疾病的发生。用CATH进行积极的CAD筛查与MI率和心脏死亡率低有关。

Heart：D-二聚体与急性心肌梗死后心衰发生率和死亡率的关系

D-二聚体与AMI患者住院后HF的发生率和全因死亡率有关。

JAMA Intern Med：PCI策略与急性心肌梗死和心源性休克患者不良预后

近年来急性心肌梗死和心源性休克患者接受多血管经皮冠状动脉介入治疗的比例逐年增加，但相比于主要梗死血管PCI，多血管PCI后患者的不良预后率也显著增加

J Am Coll Cardiol ：仅四分之一急性心肌梗死合并心源性休克患者实现了完全血运重建，残余SYNTAX评分与这类患者的死亡率独立相关

在多支血管病变合并心肌梗死（MI）相关心源性休克（CS）患者中，使用多支血管PCI策略治疗的患者中只有1/4能够实现完全血运重建。残余SYNTAX评分与早期和晚期死亡率独立相关。

Heart：中国复发性急性心肌梗死发病率、预测因素和预后影响

三分之一的AMI复发事件发生较早。复发性AMI与1年死亡率密切相关，尤其是发生于早期的患者。在此早期加强监护并改善推荐的出院药物处方可能会减少复发性AMI。

Acta Med Indones：口服N-乙酰半胱氨酸补充剂可改善急性心肌梗死患者的免疫系统

炎症、氧化应激和纤维化在急性心肌梗死（AMI）事件后起着重要作用。心血管疾病中研究最多的炎症生物标志物是C反应蛋白（CRP）。已有研究表明，AMI事件发生时，髓过氧化物酶（MPO）和Galectin-

Baidu
map
Baidu
map
Baidu
map